Jeryl L. Hilleman net worth and biography

Jeryl Hilleman Biography and Net Worth

Director of SI-BONE

Jeryl Lynn Hilleman is a member of the Board of Directors and Audit Committee Chair of public and private companies including Novocure, a commercial international oncology company delivering a novel device therapy for solid tumors called Tumor Treating Fields (Nasdaq: NVCR) and Minerva Neurosciences (Nasdaq: NERV), a clinical stage company focused on innovative solutions for patients with central nervous system diseases. Previously, Ms. Hilleman served as a Director and Audit Committee Chair of Xenoport as well as of two non-profit organizations.

Ms. Hilleman served as a public company CFO for 20 years, raising over one billion dollars in equity and debt financings including completing 5 initial public offerings and several M&A transactions. Her experience spans biopharmaceuticals, medical devices, instrument and industrial companies.

Ms. Hilleman participated in the Medical Sciences program at Brown University and earned an M.B.A. from the Wharton School of Business. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several annual Silicon Valley award programs for her contributions as a CFO and as a female business leader.

What is Jeryl L. Hilleman's net worth?: The estimated net worth of Jeryl L. Hilleman is at least $203,374.25 as of June 20th, 2023. Ms. Hilleman owns 15,349 shares of SI-BONE stock worth more than $203,374 as of December 22nd. This net worth approximation does not reflect any other assets that Ms. Hilleman may own. Learn More about Jeryl L. Hilleman's net worth.
How do I contact Jeryl L. Hilleman?: The corporate mailing address for Ms. Hilleman and other SI-BONE executives is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. SI-BONE can also be reached via phone at (408) 207-0700 and via email at [email protected]. Learn More on Jeryl L. Hilleman's contact information.
Has Jeryl L. Hilleman been buying or selling shares of SI-BONE?: Jeryl L. Hilleman has not been actively trading shares of SI-BONE in the last ninety days. Learn More on Jeryl L. Hilleman's trading history.
Who are SI-BONE's active insiders?: SI-BONE's insider roster includes Jeffrey Dunn (Director), Laura Francis (CEO), John Freund (Director), Jeryl Hilleman (Director), Gregory Hinckley (Director), Michael Pisetsky (SVP), and Anthony Recupero (Insider). Learn More on SI-BONE's active insiders.
Are insiders buying or selling shares of SI-BONE?: In the last year, insiders at the sold shares 26 times. They sold a total of 80,217 shares worth more than $1,217,756.36. The most recent insider tranaction occured on November, 18th when Director Jeffrey W Dunn sold 1,609 shares worth more than $19,999.87. Insiders at SI-BONE own 3.9% of the company. Learn More about insider trades at SI-BONE.
Information on this page was last updated on 11/18/2024.

Jeryl L. Hilleman Insider Trading History at SI-BONE

Jeryl L. Hilleman Buying and Selling Activity at SI-BONE

SI-BONE Company Overview

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Today's Range

Now: $13.25

$12.76

$13.37

50 Day Range

MA: $13.42

$12.15

$16.05

2 Week Range

Now: $13.25

$11.70

$21.70

Volume

496,538 shs

Average Volume

383,329 shs

Market Capitalization

$555.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.